Latigo Biotherapeutics Inc.

LTGO

Healthcare|Medical - Pharmaceuticals|US

$12.60

-0.41 (-3.15%)

About

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Stock Price

-31.0%(1Y)

-14.8%

-31.0%

YTD

-31.0%

Pipeline Summary

9 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 7Not Yet Recruiting: 1Active: 1

Active Trials (1)

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

NCT06049095Healthy

Phase 1Active

Enrollment: 204 participants

Key Facts

Market Cap$757.9M

Employees66

CEONima Farzan

IPO DateAug 7, 2026

Beta0.00

52-Week Range$10.24 – $25.93

Avg Volume338,105

ExchangeNASDAQ

Websitelatigobio.com